TG Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 35 U.S.-traded ETFs. TGTX has around 8.1M shares in the U.S. ETF market. The largest ETF holder of TGTX is the SPDR S&P Biotech ETF (XBI), with approximately 3.31M shares. Investors may also find of interest that the ETF with the largest allocation to TGTX stock is SPDR S&P Biotech ETF (XBI), with a portfolio weight of 1.17%. On average, U.S. ETFs allocate 0.20% of TGTX to their portfolios.
Additionally, TGTX is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with TGTX as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 48.59%.